Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency ex vivo without T cell activation

• Main Authors: Jesper D. Gunst (Author), Kathrine Kjær (Author), Rikke Olesen (Author), Thomas A. Rasmussen (Author), Lars Østergaard (Author), Paul W. Denton (Author), Ole S. Søgaard (Author), Martin Tolstrup (Author)
• Format: Book
• Published: Elsevier, 2019-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objectives: To test the potential of fimepinostat (CUDC-907), a dual inhibitor of histone deacetylases (HDAC) and phosphatidylinositol-3-kinases (PI3K), to reverse human immunodeficiency virus type 1 (HIV-1) latency in infected cell lines and in CD4+ T cells from HIV-1-infected donors on long-term c...